{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemzar&page=13", "query": { "intervention": "Gemzar", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 1629, "total_pages": 163, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemzar&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemzar&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T03:55:44.128Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006459", "title": "Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2000-07", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2012-06-07", "last_synced_at": "2026-11-06T03:55:44.128Z", "location_count": 31, "location_summary": "Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 27 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006459" }, { "nct_id": "NCT00235235", "title": "A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Serum Collection", "type": "PROCEDURE" }, { "name": "Urine Collection", "type": "PROCEDURE" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Hoosier Cancer Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 80, "start_date": "2005-09", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2015-12-09", "last_synced_at": "2026-11-06T03:55:44.128Z", "location_count": 10, "location_summary": "Bloomington, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 4 more", "locations": [ { "city": "Bloomington", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00235235" }, { "nct_id": "NCT00089024", "title": "Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "19 Years to 120 Years" }, "enrollment_count": 29, "start_date": "2004-02-25", "completion_date": "2014-12-01", "has_results": true, "last_update_posted_date": "2023-09-29", "last_synced_at": "2026-11-06T03:55:44.128Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089024" }, { "nct_id": "NCT02252887", "title": "Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic HER2-Positive Breast Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 45, "start_date": "2015-01-12", "completion_date": "2025-07-24", "has_results": true, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-11-06T03:55:44.128Z", "location_count": 5, "location_summary": "Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 2 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02252887" }, { "nct_id": "NCT00075686", "title": "S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 766, "start_date": "2004-01", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2015-11-17", "last_synced_at": "2026-11-06T03:55:44.128Z", "location_count": 382, "location_summary": "Mobile, Alabama • Opelika, Alabama • Anchorage, Alaska + 276 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Opelika", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00075686" }, { "nct_id": "NCT07377045", "title": "Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma Metastatic" ], "interventions": [ { "name": "OMTX705", "type": "DRUG" }, { "name": "Nab-paclitaxel + Gemcitabine", "type": "DRUG" }, { "name": "Tislelizumab (i.v. 200mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncomatryx Biopharma S.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2025-10-28", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-06T03:55:44.128Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07377045" }, { "nct_id": "NCT01327794", "title": "Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2011-06", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2016-06-29", "last_synced_at": "2026-11-06T03:55:44.128Z", "location_count": 1, "location_summary": "Glens Falls, New York", "locations": [ { "city": "Glens Falls", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01327794" }, { "nct_id": "NCT01431794", "title": "Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "LDE225-600mg", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "LDE225-400mg", "type": "DRUG" }, { "name": "LDE225-800mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2011-12-27", "completion_date": "2018-11-05", "has_results": true, "last_update_posted_date": "2020-01-22", "last_synced_at": "2026-11-06T03:55:44.128Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01431794" }, { "nct_id": "NCT02951156", "title": "Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Avelumab", "type": "BIOLOGICAL" }, { "name": "Utomilumab", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Azacitidine", "type": "OTHER" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2016-12-16", "completion_date": "2019-12-02", "has_results": true, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-11-06T03:55:44.128Z", "location_count": 9, "location_summary": "Duarte, California • Louisville, Kentucky • New Orleans, Louisiana + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02951156" }, { "nct_id": "NCT01893294", "title": "Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Duct Cell Adenocarcinoma of the Pancreas", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2013-04", "completion_date": "2015-10-30", "has_results": false, "last_update_posted_date": "2017-03-22", "last_synced_at": "2026-11-06T03:55:44.128Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01893294" } ] }